AXIM BIOTECHNOLOGIES, INC. — Income Charts
11 years of history · ending 2023-12-31 · SEC EDGAR
Source:10-K · 10-Q
Couldn't parse the FROM/TO range — please re-select. (No annual periods in range [2024, 2024])
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-16.9% -$8K
$40K
Cost of Revenue
$9K
Gross Profit
$187K
R&D↓-90.7% -$1M
$125K
SG&A
$2M
D&A↑+12624.0% +$424K
$427K
Operating Income↑+12.6% +$398K
$-3M
EBITDA↑+26.1% +$822K
$-2M
Interest Expense↓-55.6% -$175K
$140K
Interest Income
$0
Other Income/Expense↓-632.4% -$4M
$-5M
Pretax Income↓-93.4% -$4M
$-8M
Tax Provision
$0
Net Income↓-93.4% -$4M
$-8M
Gross Margin
95.6%
Operating Margin↓-341.5pts
-6961.0%
Net Margin↓-11633.3pts
-20395.0%
Effective Tax Rate↑+0.0pts
0.0%
Deferred Tax Assets
$0
DTA Valuation Allowance↑+504.0% +$13M
$10M
NOL Carryforwards↑+263.0% +$7M
$9M
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↓-13.0pts
21.0%
ETR State + Local (pp)↑+6.5pts
11.9%
Operating Lease Cost
$99K
Revenue YoY Variation↑+344.2pts
345.3%
Income YoY Variation↑+24.6pts
40.9%